Background. Saccharomyces cerevisiae (also known as "baker's yeast" or "brewer's yeast") is mostly considered to be an occasional digestive commensal. However, since the 1990s, there have been a growing number of reports about its implication as an etiologic agent of invasive infection. A particular feature of such infections is their association with a probiotic preparation of Saccharomyces boulardii (a subtype of S. cerevisiae) for treatment various diarrheal disorders.
teristics are not pathognomonic of the subtype. Although restriction-enzyme analysis of mitochondrial DNA [5, 6] or karyotyping [7, 8] are the tests most frequently used to identify S. boulardii, these methods have yet to be fully evaluated, notably for their discriminatory power and, thus, for their ability to unambiguously identify S. boulardii. In our experience, internal transcribed spacer sequencing has failed to discriminate S. boulardii from some S. cerevisiae strains [9] (C.H., unpublished data). To our knowledge, determination of the length of a particular microsatellite-containing locus, which was performed by Hennequin et al. [10] on 67 S. cerevisiae strains and 24 S. boulardii isolates, is the only published method that reliably distinguishes between S. boulardii and other S. cerevisiae strains.
The rate of Saccharomyces carriage varies according to the populations investigated. A study from the 1940s reported that the respiratory tract of 7% of patients with chronic pulmonary disease was colonized with Saccharomyces organisms [11] . Occasionally, S. cerevisiae can be isolated from the vaginal flora (0.9%-5.8% of women) [12, 13] , and S. cerevisiae is considered to be responsible for symptoms mimicking Candida vaginitis in 0.4% of cases [14, 15] . A more recent study involving patients with hematologic disease reported isolation of S. cerevisiae from throat, stool, urine, and perineum samples in 16%, 23%, 10%, and 20% of the patients, respectively [16] . It is not known whether S. cerevisiae is a persistent commensal of the digestive tract or whether it is only transiently present after food ingestion. Interestingly, among 70 patients hospitalized for bone marrow transplantation, S. cerevisiae was isolated only once, despite weekly surveillance cultures (primarily of stool and throat swab specimens) during hospitalization [17] . Since the 1980s, S. cerevisiae has also been isolated from persons with pathogenic conditions and has been considered to be a cause of invasive fungal infections. The incidence of Saccharomyces fungemia varied from 1% in a retrospective study of 102 nosocomial cases of fungemia [18] to 3.6% among patients at French teaching hospitals [9] . Among these cases, there is a growing number of observations regarding invasive infections with S. boulardii. To generate hypotheses for future evaluation of preventive strategies, we performed a comprehensive review of published reports of invasive Saccharomyces infections, with an emphasis on epidemiologic and clinical characteristics and the differences between S. cerevisiae and S. boulardii invasive infections.
MATERIALS AND METHODS
We reviewed published reports of invasive Saccharomyces infection found in the Medline database. The following key words were searched: "Saccharomyces," "epidemiology," "invasive," "infection," "sepsis," and "fungemia." Reports published through May 2005 in English, French, German, or Spanish were reviewed. We only considered proven infection, based on the definitions of the Invasive Fungal Infection Cooperative Group of the European Organization for Research and Treatment of Cancer-Mycosis Study Group of the National Institute of Allergy and Infectious Diseases cooperative group [19] : fungemia, isolation from normally sterile fluids (e.g., pleural and synovial fluids), and deep-site infections either histologically proven for sites susceptible to colonization (lungs, peritoneum, esophagus) [20, 21] . We did not include asymptomatic patients with only 1 organism isolated from the peritoneal cavity after digestive perforation or surgery, or from urine, oral swab, stool, or vaginal swab specimens, because such patients were more likely to have colonization rather than true infection [20] [21] [22] . Patients with insufficient clinical information were excluded [7, 18] .
We considered S. boulardii to be the etiologic agent if the patient received treatment with a probiotic containing S. boulardii and/or if a molecular typing method confirmed the identification of this pathogen. Data on age, sex, underlying disease, immunological status, previous antibiotic therapy, and intravenous catheter use were collected for each case. Immunodeficiency was considered when hematological malignancy, bone marrow transplantation, neoplasia, profound neutropenia, immunosuppressive therapy, or AIDS were reported. Profound neutropenia was defined as an absolute neutrophil count of ! neutrophils/L at the time of Saccharomyces isolation. 9 0.5 ϫ 10 Antibiotic therapy was taken into account as a possible predisposing factor when given for at least 1 week before the isolation of Saccharomyces organisms.
Antifungal treatment and removal of intravenous catheter were also recorded. The outcome was considered to be favorable if the patient survived or if the infection was cured (e.g., culture results after treatment were negative). We also investigated in vitro susceptibility by reviewing studies that included 110 isolates that underwent susceptibility testing by means of commercially available compounds.
Statistical analysis. Values are unless othermeans ‫ע‬ SD wise specified. Comparisons between groups were performed using Fisher's exact test for continuous variables and a x 2 test for percentages. P values of !.05 were considered to be statistically significant.
RESULTS
In a comprehensive review, we found 92 documented cases of proven invasive Saccharomyces infection. Fifteen cases (16.3%) were diagnosed before 1990, and 76 cases (82.6%) were diagnosed after 1990. The age of the participants was 44.3 ‫ע‬ 26.9 years; the youngest patient was 9 days old, and the oldest patient was 89 years old (tables 1 and 2). The sex ratio was 0.74 ( ) than were patients with localized (i.e., single-organ) P ! .02 infection.
Underlying conditions. All patients had at least 1 condition facilitating the development of invasive fungal infection. Intravenous catheter use (by 47 patients) and previous receipt of antibiotic therapy (by 45 patients) were the most frequently reported predisposing factors (tables 1 and 2). S. boulardii was considered to be the etiologic agent in 37 cases. Molecular identification was performed in 23 cases, mainly by means of restriction-enzyme analysis of mitochondrial DNA (table 2) . Among the 37 patients with presumed S. boulardii infection, 5 did not take a probiotic containing S. boulardii at the time of diagnosis.
Compared with patients infected with S. cerevisiae, patients infected with S. boulardii were more likely to have digestive tract disease (5.6% vs. 58.3%; ), to have an intravenous P ! .001 catheter (29% vs. 83.8%;
), and to be hospitalized in P ! .0001 NOTE. The majority of in vitro activities of antifungal agents were determined using the microdilution method (NCCLS) with Roswell Park Memorial Institute 1640 medium. ND, not done.
a Antifungal in vitro activities were determined using the microdilution method (NCCLS) with yeast nitrogen base medium. b Antifungal in vitro activities performed using Etest (AB Biodisk) and/or the microdilution method (NCCLS).
an intensive care unit (0.05% vs. 32.4%; ). In contrast, P ! .01 the frequency of immunocompromise was lower among patients infected with S. boulardii than among patients infected with S. cerevisiae (25% vs. 58.5%;
). P ! .01 Involved sites. Saccharomyces organisms were most frequently isolated from blood (72 patients), either exclusively (63 patients) or with involvement of other organ(s) (9 patients) (table 1). S. boulardii was exclusively isolated from blood ( ). Concomitant isolation of S. cerevisiae and a second n p 37 microorganism, mainly enterobacteria, was reported in 7 cases of fungemia. Patient 10 received a postmortem diagnosis of disseminated infection, although positive blood culture results were not recorded before death. In the remaining 17 cases, the infection was localized to a single organ. Overall, the main sites were the lungs (for 8 patients) and the heart valves (for 6 patients).
Treatment and outcome. Therapy was specified for 81 patients (tables 1 and 2). Of these patients, 64 received antifungal therapy, with intravenous amphotericin B alone (31 patients) or in combination with other agents (7 patients) and fluconazole (19 patients) being the most frequently administered firstline therapy. At the time of S. cerevisiae isolation, 6 patients were receiving antifungal therapy: 4 were receiving fluconazole prophylaxis, and 2 were receiving curative treatment with ketoconazole or itraconazole. Of the 32 patients for whom action regarding the catheter was reported, 27 had had their catheter removed.
Outcome was reported in 84 cases and was considered to be favorable in 57 (68.7%). Patients with S. boulardii infection had a better prognosis than patients with S. cerevisiae infection (73% vs. 55.5%;
). The rates of favorable outcome among im-P ! .01 munocompromised patients (65.5%) and immunocompetent patients (73.8%) did not differ significantly. There was no significant difference in the rates of favorable outcome between patients treated with intravenous amphotericin B (77.7%) and patients treated with fluconazole (60%).
Results of in vitro susceptibility tests. We found 9 studies in which 110 isolates underwent antifungal susceptibility testing. The results are reported in table 3.
DISCUSSION
On the basis of data revealed in our literature search, invasive Saccharomyces infections remain rare among invasive fungal infections, although the incidence has significantly increased since the 1990s. Risk factors associated with invasive Saccharomyces infections are similar to those reported elsewhere for invasive candidiasis, except for treatment with a probiotic containing S. boulardii. It is important to emphasize the role of this biotherapeutic agent, because it was responsible for 40.2% of invasive Saccharomyces infections reported in the literature. In the 5 cases in which S. boulardii was considered to be the etiologic agent, although these patients did not take a probiotic preparation, the similarity of the genotypic profile between S. boulardii isolates from patients and from probiotic preparations strongly suggested nosocomial acquisition, with catheters being a likely portal of entry because of possible contamination through hand transmission [6, 7] .
The epidemiologic characteristics of S. cerevisiae infection in human beings is not fully understood. Persistent digestive implantation in healthy volunteers has never been described, suggesting that S. cerevisiae behaves mainly as a transient digestive commensal linked to contaminated food. Thus, the portal of entry for invasive infections is mainly supposed to be digestive. Evidence suggests that nosocomial acquisition of S. cerevisiae can occur, because clusters of identical isolates from patients concurrently hospitalized in the same unit have been described [17] . This is also supported by the increasing rates of colonization among hospitalized patients with hematologic disease who only ingest sterile food not comprised of raw fruits or vegetables [16] . The same conclusion could be drawn for S. boulardii infection in patients who did not receive treatment with a probiotic containing S. boulardii, with intravenous catheters the likely portal of entry [5] . Hand transmission has been suggested in these latter cases [5] .
Saccharomyces infection is clinically indistinguishable from invasive candidiasis, notably because chorioretinitis (fluffy yellow exudates) and esophagitis (yellow-white plaques on an erythematous background) are present in both conditions, and is even indistinguishable from infections due to other microorganisms, such as endocarditis. In addition, patients have nonspecific symptoms that could be related to the underlying disease, and the diagnosis of Saccharomyces infection is often unexpected. Fever, when noted, is present in 75.2% of patients. However, the clinical impact of Saccharomyces infection has been clearly assessed in an immunocompetent patient whose unique predisposing factor was the ingestion of health food containing viable yeasts [25] . The patient developed recurrent fever, malaise with nausea, and night sweats. Yeasts were isolated from bone marrow and urine specimens. The patient recovered when he stopped ingesting health food containing yeasts. The occurrence of deep-site involvement with histologic documentation also underlines the pathogenicity of such yeasts. In these cases, yeasts were most often associated with necrosis [60] and granulomatous reaction [25] .
Significant particularities of S. boulardii infections include higher frequency of intensive care unit hospitalization, presence of an indwelling catheter, and intestinal disease. This may either correspond to specific predisposing factors or, more likely, may reflect conditions associated with treatment with a probiotic containing S. boulardii, such as severe digestive disease. The lack of organ involvement and the better prognosis could be due to decreased S. boulardii virulence. Another explanation could be the ability of patients at risk to partly control the infection, given the lower frequency of immunocompromise in this group. S. boulardii showed an intermediate level of virulence in an experimental murine model of invasive infection involving both immunocompetent and immunocompromised mice [3] .
S. cerevisiae has, in immunocompromised mice, been shown to grow at 42ЊC and to form pseudohyphae [84] . Also, SSD1, which encodes a protein that affects various cellular processes (including maintenance of cell integrity, control of cell cycle, and growth at high temperature), seems to play an important role in the virulence of Saccharomyces organisms [85] . Deletion of this gene leads to a significant increase in virulence for both clinical and plant isolates, as revealed in a mouse model of invasive infection [85] . Alteration in composition and cell wall architecture is supposed to lead to overstimulation of the proinflammatory response. Furthermore, analysis of feral and clinical strains of S. cerevisiae showed similar virulence in a mouse model of infection [85] . Similar to many opportunistic organisms, it is not possible to identify particular features of S. cerevisiae that distinguish between environmental and clinical strains on the basis of virulence-related phenotype [84] .
S. cerevisiae exhibits low susceptibility to amphotericin B and to azole derivatives (table 3) . Although breakpoints have not been defined for S. cerevisiae, MIC 90 for fluconazole and itraconazole are considered to be within the susceptible dosedependent range defined for C. albicans [86] . One can hypothesize that these drugs may play a role in the emergence of S. cerevisiae. Although data remain scarce, voriconazole seems to exhibit good efficacy against S. cerevisiae, with an MIC 90 of !0.25 mg/L. A recent publication reports on the successful outcome with voriconazole therapy for a patient with S. boulardii who did not respond to initial treatment with fluconazole [76] . No published series is available for caspofungin treatment, but preliminary research has demonstrated good efficacy against a limited number of strains (C.H., unpublished data). MIC values for amphotericin B and fluconazole were 0.19 and 32 mg/L, respectively, as determined for 2 clinical isolates of S. boulardii [5] . S. boulardii could not be tested by Etest (AB Biodisk) on casitone or Roswell Park Memorial Institute 1640 agar because of the lack of growth on these media (A.E.-A. and C.H., unpublished data).
Despite this spectrum of susceptibility, a favorable outcome was observed in 63% of cases revealed in our literature search, which is a slightly higher percentage than that reported for cases of invasive candidiasis [87] . Specific data on morbidity were difficult to evaluate, because Saccharomyces infections often occurred in patients with a large number of comorbidities. Use of amphotericin B or fluconazole therapy with central venous catheter removal appeared to be an effective therapeutic option for patients with Saccharomyces infection. Favorable outcome may also be related to the low virulence of this species, a hypothesis that is supported by the absence of significant difference in outcome between immunocompromised and immunocompetent patients.
In conclusion, Saccharomyces organisms are increasingly reported as agents of invasive infection, especially in immunocompromised or critically ill patients. Special caution has to be taken with S. boulardii probiotic preparations, which account for nearly 40% of infection cases.
